Although some studies suggest that patients with high TMB may exhibit better responses to immunotherapy, therapeutic efficacy is concurrently influenced by factors such as the tumor microenvironment, immune evasion mechanisms, tumor-infiltrating lymphocytes (TILs), and PD-L1 expression. This evidence concerns the gene CD274 and neoplasm.